Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Videos|November 29, 2021
Expert: Specialty Pharmacy is Changing, “Needs to Go Where the Patients Are” in the Future
Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, provides an analysis and overview of key specialty pharmaceuticals in development.
Advertisement
Pharmacy Times interviewed Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, on his presentation at the Asembia 2021 Specialty Summit on specialty pharmaceuticals in development.
During the discussion, Tancredi addressed some of the key trends in specialty drug development of late, how the category of “specialty pharmacy” is changing within the field, and some recent FDA approvals that are uniquely impacting the market.
Advertisement
Related to this article
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5